154 related articles for article (PubMed ID: 30593980)
41. Randomised, double blind, placebo controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves.
Liu C; Blumhardt LD
J Neurol Neurosurg Psychiatry; 1999 Oct; 67(4):451-6. PubMed ID: 10486390
[TBL] [Abstract][Full Text] [Related]
42. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.
Segal BM; Constantinescu CS; Raychaudhuri A; Kim L; Fidelus-Gort R; Kasper LH;
Lancet Neurol; 2008 Sep; 7(9):796-804. PubMed ID: 18703004
[TBL] [Abstract][Full Text] [Related]
43. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
Gold R; Kappos L; Arnold DL; Bar-Or A; Giovannoni G; Selmaj K; Tornatore C; Sweetser MT; Yang M; Sheikh SI; Dawson KT;
N Engl J Med; 2012 Sep; 367(12):1098-107. PubMed ID: 22992073
[TBL] [Abstract][Full Text] [Related]
44. Study on Dalfampridine in the treatment of Multiple Sclerosis Mobility Disability: A meta-analysis.
Shi J; Wu X; Chen Y
PLoS One; 2019; 14(9):e0222288. PubMed ID: 31513613
[TBL] [Abstract][Full Text] [Related]
45. Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study.
Adler LA; Dirks B; Deas PF; Raychaudhuri A; Dauphin MR; Lasser RA; Weisler RH
J Clin Psychiatry; 2013 Jul; 74(7):694-702. PubMed ID: 23945447
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of 4-aminopyridine in patients with long-term spinal cord injury: a randomized, double-blind, placebo-controlled trial.
Grijalva I; Guízar-Sahagún G; Castañeda-Hernández G; Mino D; Maldonado-Julián H; Vidal-Cantú G; Ibarra A; Serra O; Salgado-Ceballos H; Arenas-Hernández R
Pharmacotherapy; 2003 Jul; 23(7):823-34. PubMed ID: 12885095
[TBL] [Abstract][Full Text] [Related]
47. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
48. Neuroenhancement through cognitive training and anodal tDCS in multiple sclerosis.
Mattioli F; Bellomi F; Stampatori C; Capra R; Miniussi C
Mult Scler; 2016 Feb; 22(2):222-30. PubMed ID: 26014600
[TBL] [Abstract][Full Text] [Related]
49. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
Goodman AD; Brown TR; Krupp LB; Schapiro RT; Schwid SR; Cohen R; Marinucci LN; Blight AR;
Lancet; 2009 Feb; 373(9665):732-8. PubMed ID: 19249634
[TBL] [Abstract][Full Text] [Related]
50. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.
Giovannoni G; Gold R; Selmaj K; Havrdova E; Montalban X; Radue EW; Stefoski D; McNeill M; Amaravadi L; Sweetser M; Elkins J; O'Neill G;
Lancet Neurol; 2014 May; 13(5):472-81. PubMed ID: 24656609
[TBL] [Abstract][Full Text] [Related]
51. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study.
Selmaj K; Li DK; Hartung HP; Hemmer B; Kappos L; Freedman MS; Stüve O; Rieckmann P; Montalban X; Ziemssen T; Auberson LZ; Pohlmann H; Mercier F; Dahlke F; Wallström E
Lancet Neurol; 2013 Aug; 12(8):756-67. PubMed ID: 23764350
[TBL] [Abstract][Full Text] [Related]
52. Donepezil improved memory in multiple sclerosis in a randomized clinical trial.
Krupp LB; Christodoulou C; Melville P; Scherl WF; MacAllister WS; Elkins LE
Neurology; 2004 Nov; 63(9):1579-85. PubMed ID: 15534239
[TBL] [Abstract][Full Text] [Related]
53. Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.
Sorensen PS; Lycke J; Erälinna JP; Edland A; Wu X; Frederiksen JL; Oturai A; Malmeström C; Stenager E; Sellebjerg F; Sondergaard HB;
Lancet Neurol; 2011 Aug; 10(8):691-701. PubMed ID: 21742556
[TBL] [Abstract][Full Text] [Related]
54. Randomized placebo-controlled adjunctive study of an extract of withania somnifera for cognitive dysfunction in bipolar disorder.
Chengappa KN; Bowie CR; Schlicht PJ; Fleet D; Brar JS; Jindal R
J Clin Psychiatry; 2013 Nov; 74(11):1076-83. PubMed ID: 24330893
[TBL] [Abstract][Full Text] [Related]
55. Effect of Chlorogenic Acids on Cognitive Function in Mild Cognitive Impairment: A Randomized Controlled Crossover Trial.
Ochiai R; Saitou K; Suzukamo C; Osaki N; Asada T
J Alzheimers Dis; 2019; 72(4):1209-1216. PubMed ID: 31683483
[TBL] [Abstract][Full Text] [Related]
56. High dose Vitamin D intake and quality of life in relapsing-remitting multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial.
Ashtari F; Toghianifar N; Zarkesh-Esfahani SH; Mansourian M
Neurol Res; 2016 Oct; 38(10):888-92. PubMed ID: 27597724
[TBL] [Abstract][Full Text] [Related]
57. Computer-assisted rehabilitation of attention in patients with multiple sclerosis: results of a randomized, double-blind trial.
Amato MP; Goretti B; Viterbo RG; Portaccio E; Niccolai C; Hakiki B; Iaffaldano P; Trojano M
Mult Scler; 2014 Jan; 20(1):91-8. PubMed ID: 23959713
[TBL] [Abstract][Full Text] [Related]
58. Cognitive impairment differs between primary progressive and relapsing-remitting MS.
Ruet A; Deloire M; Charré-Morin J; Hamel D; Brochet B
Neurology; 2013 Apr; 80(16):1501-8. PubMed ID: 23516324
[TBL] [Abstract][Full Text] [Related]
59. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).
Comi G; Patti F; Rocca MA; Mattioli FC; Amato MP; Gallo P; Centonze D; Pozzilli C; Saccà F; Bergh FT; Bartezaghi M; Turrini R; Filippi M;
J Neurol; 2017 Dec; 264(12):2436-2449. PubMed ID: 29063244
[TBL] [Abstract][Full Text] [Related]
60. Effects of adjunct glucosamine sulfate on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized, placebo-controlled trial.
Shaygannejad V; Janghorbani M; Savoj MR; Ashtari F
Neurol Res; 2010 Nov; 32(9):981-5. PubMed ID: 20223094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
